These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

238 related items for PubMed ID: 9326205

  • 1. Allogeneic marrow transplantation for primary myelofibrosis and myelofibrosis secondary to polycythaemia vera or essential thrombocytosis.
    Anderson JE, Sale G, Appelbaum FR, Chauncey TR, Storb R.
    Br J Haematol; 1997 Sep; 98(4):1010-6. PubMed ID: 9326205
    [Abstract] [Full Text] [Related]

  • 2. Allogeneic hematopoietic stem cell transplantation in patients with polycythemia vera or essential thrombocythemia transformed to myelofibrosis or acute myeloid leukemia: a report from the MPN Subcommittee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation.
    Lussana F, Rambaldi A, Finazzi MC, van Biezen A, Scholten M, Oldani E, Carobbio A, Iacobelli S, Finke J, Nagler A, Volin L, Lamy T, Arnold R, Mohty M, Michallet M, de Witte T, Olavarria E, Kröger N.
    Haematologica; 2014 May; 99(5):916-21. PubMed ID: 24389309
    [Abstract] [Full Text] [Related]

  • 3. Allogeneic Hematopoietic Stem Cell Transplantation for Post-essential Thrombocythemia and Post-polycythemia Vera Myelofibrosis.
    Murata M, Suzuki R, Nishida T, Shirane S, Shimazu Y, Minami Y, Mori T, Doki N, Kanda Y, Uchida N, Tanaka M, Ishikawa J, Togitani K, Fukuda T, Ichinohe T, Atsuta Y, Nagamura-Inoue T, Kiyoi H.
    Intern Med; 2020 May; 59(16):1947-1956. PubMed ID: 32801269
    [Abstract] [Full Text] [Related]

  • 4. Comparison of Dynamic International Prognostic Scoring System and MYelofibrosis SECondary to PV and ET Prognostic Model for Prediction of Outcome in Polycythemia Vera and Essential Thrombocythemia Myelofibrosis after Allogeneic Stem Cell Transplantation.
    Gagelmann N, Eikema DJ, de Wreede LC, Koster L, Wolschke C, Arnold R, Kanz L, McQuaker G, Marchand T, Socié G, Bourhis JH, Mohty M, Cornelissen JJ, Chevallier P, Bernasconi P, Stelljes M, Rohrlich PS, Fanin R, Finke J, Maertens J, Blaise D, Itälä-Remes M, Labussière-Wallet H, Robin M, McLornan D, Chalandon Y, Yakoub-Agha I, Kröger N, CMWP of the European Society for Blood and Marrow Transplantation.
    Biol Blood Marrow Transplant; 2019 Jun; 25(6):e204-e208. PubMed ID: 30930192
    [Abstract] [Full Text] [Related]

  • 5. Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia.
    Kerbauy DM, Gooley TA, Sale GE, Flowers ME, Doney KC, Georges GE, Greene JE, Linenberger M, Petersdorf E, Sandmaier BM, Scott BL, Sorror M, Stirewalt DL, Stewart FM, Witherspoon RP, Storb R, Appelbaum FR, Deeg HJ.
    Biol Blood Marrow Transplant; 2007 Mar; 13(3):355-65. PubMed ID: 17317589
    [Abstract] [Full Text] [Related]

  • 6. Allogeneic hematopoietic stem cell transplantation for myelofibrosis.
    Deeg HJ, Gooley TA, Flowers ME, Sale GE, Slattery JT, Anasetti C, Chauncey TR, Doney K, Georges GE, Kiem HP, Martin PJ, Petersdorf EW, Radich J, Sanders JE, Sandmaier BM, Warren EH, Witherspoon RP, Storb R, Appelbaum FR.
    Blood; 2003 Dec 01; 102(12):3912-8. PubMed ID: 12920019
    [Abstract] [Full Text] [Related]

  • 7. Transplant decision-making strategies in the myeloproliferative disorders.
    Fruchtman SM.
    Semin Hematol; 2003 Jan 01; 40(1 Suppl 1):30-3. PubMed ID: 12682880
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Allogeneic bone marrow transplantation for agnogenic myeloid metaplasia. French Society of Bone Marrow Transplantation.
    Guardiola P, Esperou H, Cazals-Hatem D, Ifrah N, Jouet JP, Buzyn A, Sutton L, Gratecos N, Tilly H, Lioure B, Gluckman E.
    Br J Haematol; 1997 Sep 01; 98(4):1004-9. PubMed ID: 9326204
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Progression of bone marrow fibrosis in patients with essential thrombocythemia and polycythemia vera during anagrelide treatment.
    Hultdin M, Sundström G, Wahlin A, Lundström B, Samuelsson J, Birgegård G, Engström-Laurent A.
    Med Oncol; 2007 Sep 01; 24(1):63-70. PubMed ID: 17673813
    [Abstract] [Full Text] [Related]

  • 13. Phase II trial of panobinostat, an oral pan-deacetylase inhibitor in patients with primary myelofibrosis, post-essential thrombocythaemia, and post-polycythaemia vera myelofibrosis.
    DeAngelo DJ, Mesa RA, Fiskus W, Tefferi A, Paley C, Wadleigh M, Ritchie EK, Snyder DS, Begna K, Ganguly S, Ondovik MS, Rine J, Bhalla KN.
    Br J Haematol; 2013 Aug 01; 162(3):326-35. PubMed ID: 23701016
    [Abstract] [Full Text] [Related]

  • 14. Curative therapy of advanced essential thrombocythemia or polycythemia vera by hemopoietic stem cell transplantation.
    Platzbecker U, Gooley T, Anasetti C, Appelbaum FR, Clurman B, Doney K, Chauncey T, Flowers ME, Myerson D, Radich JP, Storb R, Witherspoon RP, Deeg HJ.
    Leuk Lymphoma; 2002 Jul 01; 43(7):1409-14. PubMed ID: 12389621
    [Abstract] [Full Text] [Related]

  • 15. Haemopoietic stem cell transplantation for advanced polycythaemia vera or essential thrombocythaemia.
    Jurado M, Deeg H, Gooley T, Anasetti C, Chauncey T, Flowers M, Myerson D, Storb R, Appelbaum F.
    Br J Haematol; 2001 Feb 01; 112(2):392-6. PubMed ID: 11167837
    [Abstract] [Full Text] [Related]

  • 16. Splenic irradiation as a component of a reduced-intensity conditioning regimen for hematopoietic stem cell transplantation in myelofibrosis with massive splenomegaly.
    Ito T, Akagi K, Kondo T, Kawabata H, Ichinohe T, Takaori-Kondo A.
    Tohoku J Exp Med; 2012 Dec 01; 228(4):295-9. PubMed ID: 23117264
    [Abstract] [Full Text] [Related]

  • 17. The evolving understanding of prognosis in post-essential thrombocythemia myelofibrosis and post-polycythemia vera myelofibrosis vs primary myelofibrosis.
    Masarova L, Verstovsek S.
    Clin Adv Hematol Oncol; 2019 May 01; 17(5):299-307. PubMed ID: 31188809
    [Abstract] [Full Text] [Related]

  • 18. A phase I study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post-polycythaemia vera/essential thrombocythaemia myelofibrosis (post-PV/ET MF).
    Mascarenhas J, Lu M, Li T, Petersen B, Hochman T, Najfeld V, Goldberg JD, Hoffman R.
    Br J Haematol; 2013 Apr 01; 161(1):68-75. PubMed ID: 23330839
    [Abstract] [Full Text] [Related]

  • 19. Dynamic International Prognostic Scoring System scores, pre-transplant therapy and chronic graft-versus-host disease determine outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis.
    Ditschkowski M, Elmaagacli AH, Trenschel R, Gromke T, Steckel NK, Koldehoff M, Beelen DW.
    Haematologica; 2012 Oct 01; 97(10):1574-81. PubMed ID: 22491742
    [Abstract] [Full Text] [Related]

  • 20. Allogeneic haematopoietic cell transplantation for myelofibrosis in 30 patients 60-78 years of age.
    Samuelson S, Sandmaier BM, Heslop HE, Popat U, Carrum G, Champlin RE, Storb R, Prchal JT, Gooley TA, Deeg HJ.
    Br J Haematol; 2011 Apr 01; 153(1):76-82. PubMed ID: 21323890
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.